At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 206 enrolled
Drug / intervention
Mirvetuximab soravtansinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Mirvetuximab soravtansine for Tumors. Completed, enrolled 206 participants across 12 sites in 2 countries.
Detailed Summary
The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
CountriesCanada, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartJun 2012
Primary CompletionMar 2018
TodayJul 2026
First PostedJun 1, 2012
Enrollment StartJun 28, 2012
Primary CompletionMar 19, 2018
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 14.1 years ago
Interventions
Mirvetuximab soravtansinedrug
Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.